A Phase 1/2 Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer
Phase of Trial: Phase I/II
Latest Information Update: 26 Nov 2019
Price : $35 *
At a glance
- Drugs Alectinib (Primary)
- Indications Non-small cell lung cancer; Thyroid cancer
- Focus Adverse reactions; Therapeutic Use
- 21 Nov 2019 Status changed from active, no longer recruiting to discontinued.
- 31 Oct 2018 Status changed from recruiting to active, no longer recruiting.
- 31 Aug 2018 Biomarkers information updated